Investor Relations

Corporate profile

Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.

Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions.

Investment Highlights

Strong IP strategy for novel therapeutic modality.

Favorable safety profile demonstrated across several clinical studies.

Proposed MOA supported by clinical data.

Optimized manufacturing process yielding ready-to-use doses of off-the-shelf cell therapy platform.

Multi-billion-dollar market opportunity in several inflammatory disease markets with high unmet need.

Seasoned management team with a track record of successfully advancing therapies through regulatory approval.

Recent news releases

View all
23

April

2025

Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced th...
21

April

2025

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled...
3

April

2025

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ causes pain and stiffness in the jaw, making it difficult to chewTMJ osteoarthritis currently has...